This company listing is no longer active
LBM Stock Overview
Labomar S.p.A. researches, develops, manufactures, and sells food supplements, medical devices, cosmetics, and pharmaceutical products in Italy, France, Poland, Spain, North America, and internationally.
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 3/6 |
| Past Performance | 2/6 |
| Financial Health | 5/6 |
| Dividends | 2/6 |
Labomar S.p.A. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | €9.95 |
| 52 Week High | €10.20 |
| 52 Week Low | €7.36 |
| Beta | 0.44 |
| 1 Month Change | 0% |
| 3 Month Change | 0% |
| 1 Year Change | 17.33% |
| 3 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | 39.14% |
Recent News & Updates
Recent updates
The Returns On Capital At Labomar (BIT:LBM) Don't Inspire Confidence
Mar 28
Here's What's Concerning About Labomar's (BIT:LBM) Returns On Capital
Jul 26Estimating The Fair Value Of Labomar S.p.A. (BIT:LBM)
Feb 25Labomar's (BIT:LBM) Solid Earnings May Rest On Weak Foundations
Oct 04Estimating The Fair Value Of Labomar S.p.A. (BIT:LBM)
Jul 18Is Labomar S.p.A.'s (BIT:LBM) 40% ROE Better Than Average?
Jan 06Shareholder Returns
| LBM | IT Personal Products | IT Market | |
|---|---|---|---|
| 7D | 0% | 4.4% | -0.3% |
| 1Y | 17.3% | -3.3% | 18.1% |
Return vs Industry: LBM exceeded the Italian Personal Products industry which returned -1.8% over the past year.
Return vs Market: LBM matched the Italian Market which returned 17.2% over the past year.
Price Volatility
| LBM volatility | |
|---|---|
| LBM Average Weekly Movement | 1.0% |
| Personal Products Industry Average Movement | 4.7% |
| Market Average Movement | 4.4% |
| 10% most volatile stocks in IT Market | 7.6% |
| 10% least volatile stocks in IT Market | 2.7% |
Stable Share Price: LBM has not had significant price volatility in the past 3 months.
Volatility Over Time: LBM's weekly volatility (1%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1998 | 355 | Walter Bertin | labomar.com |
Labomar S.p.A. researches, develops, manufactures, and sells food supplements, medical devices, cosmetics, and pharmaceutical products in Italy, France, Poland, Spain, North America, and internationally. It offers food supplements for various therapeutic areas, including immune systems, gastroenterology, cough and cold, neurology, oncology, eyesight wellness, sport, dermatology, inside beauty, cardiology, orthopedics, pediatrics, detoxing, and metabolic syndrome; and vitamins, minerals, and antioxidants. The company also provides medical devices for the use in gynaecology, cough and cold, gastroenterology, wound healing, metabolic syndrome, proctology, detoxing, and oral wound care therapeutic areas; and foods for special medical purposes, such as gastroenterology, endocrinology, and dysphagia.
Labomar S.p.A. Fundamentals Summary
| LBM fundamental statistics | |
|---|---|
| Market cap | €183.92m |
| Earnings (TTM) | €6.14m |
| Revenue (TTM) | €92.98m |
29.9x
P/E Ratio2.0x
P/S RatioIs LBM overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| LBM income statement (TTM) | |
|---|---|
| Revenue | €92.98m |
| Cost of Revenue | €56.53m |
| Gross Profit | €36.44m |
| Other Expenses | €30.30m |
| Earnings | €6.14m |
Last Reported Earnings
Dec 31, 2022
Next Earnings Date
n/a
| Earnings per share (EPS) | 0.33 |
| Gross Margin | 39.20% |
| Net Profit Margin | 6.61% |
| Debt/Equity Ratio | 73.1% |
How did LBM perform over the long term?
See historical performance and comparison